Cao, Yanyan
Ouyang, Tao
Xiong, Fu
Kan, Xuefeng
Chen, Lei
Liang, Bin
Zheng, Chuansheng http://orcid.org/0000-0002-2435-1417
Funding for this research was provided by:
National Natural Science Foundation of China (81873919)
Article History
Received: 27 November 2020
Accepted: 23 April 2021
First Online: 20 August 2021
Declarations
:
: The study was conducted according to the Declaration of Helsinki. Informed consent was waived for the retrospective type of this study. The information of all participants is maintained with confidentiality. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: All patients were informed that apatinib was an alternative treatment, because the first-line sorafenib–TACE treatment was ineffective. Moreover, all patients were informed of the economic cost, anticipated outcomes, and potential toxicity. Final treatment decisions were made by the patients.